New mRNA vaccine trial aims to boost immune attack on lung cancer

NCT ID NCT07652125

Recruiting now Disease control Sponsor: Guangdong Association of Clinical Trials Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 01, 2026 · Updated 3 times

Summary

This early study will test a personalized mRNA vaccine (RGL-270) given together with standard immunotherapy drugs in 40 people with advanced non-small cell lung cancer. The vaccine is custom-made to target unique markers on each person's tumor. The main goal is to check safety and immune response, not yet to prove the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: personalized neoantigen mRNA vaccine (RGL-270) combined with a PD-1/PD-L1 inhibitor
What this could lead to: If it works, this could point toward a new treatment option that helps the immune system better attack advanced lung cancer.
What could go wrong: This is a very early, small study (40 people) that hasn't started yet. It primarily looks at safety, not whether the treatment actually works. Many early-stage cancer vaccine trials do not lead to approved treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

Contacts and locations

Locations

Guangdong Provincial Perople's Hospital
RECRUITING

Guangzhou, Other (Non U.s.), 510080, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.